Loading
A phase 3 trial of Camrelizumab, Rivoceranib in hepatocellular carcinoma, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation is a phase 3 interventional study registered as NCT04639180 by Jiangsu HengRui Medicine Co., Ltd., with 687 participants enrolled, started 2021-04-01 and due to reach its primary completion in 2026-07-31. Interventions recorded: Camrelizumab, Rivoceranib (Apatinib). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.